And the Dog Was Barking: Transforming Quality of Life in Diabetes Through Innovative Hypoglycemia Detection

IF 3.7 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM
Theocharis Koufakis, Djordje S. Popovic, Nikolaos Papanas
{"title":"And the Dog Was Barking: Transforming Quality of Life in Diabetes Through Innovative Hypoglycemia Detection","authors":"Theocharis Koufakis,&nbsp;Djordje S. Popovic,&nbsp;Nikolaos Papanas","doi":"10.1111/1753-0407.70143","DOIUrl":null,"url":null,"abstract":"<p>For people living with diabetes, hypoglycemia has long been a silent threat—its approach often as unnoticed as a dog barking in the distance, unheard by those most at risk. Since the earliest clinical descriptions of diabetes, hypoglycemia has been recognized as a critical and sometimes life-threatening complication of glucose-lowering therapy [<span>1</span>]. In the early 20th century, with the advent of insulin therapy, hypoglycemia emerged as a new and immediate concern, often identified only after the onset of severe neuroglycopenic symptoms. Early detection relied primarily on clinical observation and patient self-reporting of warning signs, with little objective measurement available. The development of capillary blood glucose testing in the 1970s and 1980s marked a major advance, enabling both patients and clinicians to more accurately identify and document hypoglycemic episodes. Over the past two decades, the evaluation of hypoglycemia has been revolutionized by continuous glucose monitoring (CGM) technologies and the integration of predictive algorithms, which now allow for real-time detection, detailed glycemic profiling, and proactive management [<span>2</span>]. This historical progression from symptom-based recognition to advanced digital monitoring reflects the ongoing commitment to improving safety and outcomes in diabetes care.</p><p>However, hypoglycemia remains a principal barrier to optimal glycemic control in diabetes, particularly for individuals with type 1 diabetes mellitus (T1DM), who require intensive insulin regimens to prevent microvascular and macrovascular complications [<span>3</span>]. While intensified therapy reduces long-term risks, it simultaneously increases the incidence of hypoglycemia, necessitating careful therapeutic balancing. A significant subset of individuals with T1DM—estimated at up to 25%—develop hypoglycemia unawareness, where autonomic warning symptoms such as sweating and tremor become attenuated or absent [<span>4</span>]. This phenomenon greatly elevates the risk for severe events requiring external assistance, often forcing patients and clinicians to accept higher glucose targets than recommended [<span>5</span>]. Thus, the fear and reality of hypoglycemia continue to restrict the full benefits of modern diabetes therapies and remain a central concern in clinical care.</p><p>The implications of hypoglycemia extend well beyond transient physical symptoms. Acute episodes have been associated with a heightened risk of cardiac arrhythmias and myocardial ischemia, linked to autonomic surges and altered cardiac repolarization [<span>6</span>]. Hypoglycemia may also induce a prothrombotic state, increasing platelet activation and coagulation, thereby further raising cardiovascular risk—an especially pertinent issue in people already predisposed to vascular disease [<span>7</span>]. At a neurological level, repeated or severe events can result in cognitive dysfunction, seizures, and, rarely, irreversible brain injury [<span>8</span>]. Importantly, the psychological toll is substantial: persistent fear of hypoglycemia can drive suboptimal self-management, such as intentional hyperglycemia, and contribute to reduced quality of life [<span>9</span>]. Fear of hypoglycemia is a multidimensional phenomenon, involving not only anxiety about experiencing the physical symptoms of hypoglycemia but also apprehension regarding the unpredictability of such episodes, potential social embarrassment, and the risk of harm to oneself or others. As highlighted by Bloomgarden [<span>10</span>], this fear can create a significant emotional burden, leading patients to consciously avoid optimal glycemic targets in order to minimize perceived risk, which paradoxically increases the likelihood of long-term diabetes complications. The need for improved detection and prevention strategies is therefore both medical and psychosocial in nature.</p><p>An intriguing example of non-technological innovation in this field is the use of diabetes alert dogs (DADs), often Labradors, trained to detect specific scent markers—volatile organic compounds—in the breath or sweat of individuals during hypoglycemic episodes [<span>11</span>]. Controlled studies and real-world experience suggest that DADs can provide early warnings before symptomatic awareness; facilitating more rapid intervention [<span>12</span>]. Furthermore, beyond physiological safety, the presence of a trained service dog offers meaningful psychosocial benefits, including reduced anxiety and increased independence, especially for children and those experiencing nocturnal hypoglycemia [<span>13</span>]. While challenges remain in standardization and evidence quality, DADs exemplify the value of integrating biological detection with patient-centered care.</p><p>Technological advances in CGM have transformed the landscape of hypoglycemia detection and prevention. CGM systems provide near-continuous, subcutaneous glucose data, delivering real-time alerts for actual or impending hypoglycemia. Numerous randomized controlled trials have shown that CGM significantly reduces the frequency and severity of hypoglycemia, especially in those with impaired awareness, while also supporting improved glycemic control [<span>14</span>]. CGM also enables trend analysis and more precise therapy adjustments, thus empowering patients and clinicians to optimize diabetes management and mitigate risk [<span>15</span>].</p><p>Sensor-augmented insulin pumps (SAPs) with low glucose suspend (LGS) and predictive low glucose suspend (PLGS) functions represent another major step forward. By integrating CGM data, these devices can automatically halt basal insulin infusion when low or dropping glucose is detected or predicted, thereby reducing the risk of severe hypoglycemia, particularly overnight. Large trials, including the ASPIRE and SMILE studies, have confirmed that SAPs with LGS/PLGS significantly decrease hypoglycemia burden without compromising overall glycemic targets, benefiting high-risk groups such as those with hypoglycemia unawareness [<span>16, 17</span>].</p><p>The latest generation of CGM and SAP devices employ artificial intelligence (AI) and machine learning to predict hypoglycemic events before they occur. AI algorithms continuously analyze large streams of glucose data, insulin dosing, and contextual factors in real time, identifying patterns and predicting when blood glucose is likely to fall below a safe threshold. In CGM systems, this can trigger timely alerts to the patient or caregiver before hypoglycemia actually develops, allowing for preventive action. In SAPs and closed-loop systems, AI not only predicts impending hypoglycemia but can automatically adjust or suspend insulin delivery to avert the event. These predictive and automated features are especially valuable at night when patients are most vulnerable and may not be aware of symptoms. Preliminary clinical studies indicate that such predictive technologies can substantially reduce nocturnal hypoglycemia and improve user confidence while the accuracy and personalization of these algorithms continue to advance [<span>18, 19</span>]. As AI-driven systems are integrated into closed-loop insulin delivery, their potential for individualized diabetes management is expected to expand further.</p><p>Non-invasive glucose monitoring using sweat, saliva, or transdermal technologies holds significant promise for the future, aiming to reduce the burden of needle-based monitoring and increase adherence. In parallel, wearable health devices—such as smartwatches—are being developed to provide multi-parameter physiologic data, enabling more robust and context-aware hypoglycemia prediction [<span>20</span>]. The evolution of closed-loop “artificial pancreas” systems, which automatically adjust insulin delivery based on real-time sensor data, is moving diabetes management closer to seamless automation, reducing both hypo- and hyperglycemic excursions [<span>21</span>]. The integration of biosensors, digital health solutions, and AI-driven analytics is expected to herald a new era of proactive, individualized diabetes management.</p><p>In conclusion, recent innovations in hypoglycemia detection—spanning from the keen instincts of trained dogs to advanced CGMs, SAPs, and AI—have redefined diabetes management. These technologies have not only reduced the risk and burden of hypoglycemia, but also alleviated its psychological consequences, enhancing quality of life and patient autonomy. Where once individuals relied on a dog's bark for protection, today's solutions ensure that warnings are timely, precise, and reliable. For many years, the dog was barking in the middle of the night; at last, now we can enjoy better sleep.</p><p>T.K. reviewed the literature and wrote the first version of the manuscript. D.S.P. and N.P. reviewed the literature and edited the manuscript. All authors have read and approved the final version of the manuscript.</p><p>T.K. is an Editorial Board member of <i>Journal of Diabetes</i> and a co-author of this article. To minimize bias, they were excluded from all editorial decision-making related to the acceptance of this article for publication. T.K. has received honoraria for lectures from AstraZeneca, Sanofi, Boehringer Ingelheim, Pharmaserve Lilly, Menarini, and Novo Nordisk, for advisory boards from Novo Nordisk, Roche, Sanofi, and Boehringer Ingelheim, and has participated in sponsored studies by Eli-Lilly, AstraZeneca, and Novo Nordisk. D.S.P. declares associations to Abbott, Alkaloid, AstraZeneca, Boehringer-Ingelheim, Berlin-Chemie, Eli Lilly, Galenika, Krka, Merck, Novo Nordisk, PharmaSwiss, Sanofi-Aventis, Servier, Viatris, ADOC Pharma, and Worwag Pharma. N.P. has been an advisory board member of TrigoCare International, Abbott, AstraZeneca, Elpen, MSD, Novartis, Novo Nordisk, Sanofi Aventis, and Takeda; has participated in sponsored studies by Eli Lilly, MSD, Novo Nordisk, Novartis, and Sanofi Aventis; received honoraria as a speaker for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Elpen, Galenica, GSK, MSD, Mylan, Novartis, Novo Nordisk, Pfizer, Sanofi Aventis, Takeda, and Vianex; and attended conferences sponsored by TrigoCare International, AstraZeneca, Boehringer Ingelheim, Eli Lilly, GSK, Novartis, Novo Nordisk, Pfizer, and Sanofi Aventis.</p>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"17 8","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70143","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/1753-0407.70143","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

For people living with diabetes, hypoglycemia has long been a silent threat—its approach often as unnoticed as a dog barking in the distance, unheard by those most at risk. Since the earliest clinical descriptions of diabetes, hypoglycemia has been recognized as a critical and sometimes life-threatening complication of glucose-lowering therapy [1]. In the early 20th century, with the advent of insulin therapy, hypoglycemia emerged as a new and immediate concern, often identified only after the onset of severe neuroglycopenic symptoms. Early detection relied primarily on clinical observation and patient self-reporting of warning signs, with little objective measurement available. The development of capillary blood glucose testing in the 1970s and 1980s marked a major advance, enabling both patients and clinicians to more accurately identify and document hypoglycemic episodes. Over the past two decades, the evaluation of hypoglycemia has been revolutionized by continuous glucose monitoring (CGM) technologies and the integration of predictive algorithms, which now allow for real-time detection, detailed glycemic profiling, and proactive management [2]. This historical progression from symptom-based recognition to advanced digital monitoring reflects the ongoing commitment to improving safety and outcomes in diabetes care.

However, hypoglycemia remains a principal barrier to optimal glycemic control in diabetes, particularly for individuals with type 1 diabetes mellitus (T1DM), who require intensive insulin regimens to prevent microvascular and macrovascular complications [3]. While intensified therapy reduces long-term risks, it simultaneously increases the incidence of hypoglycemia, necessitating careful therapeutic balancing. A significant subset of individuals with T1DM—estimated at up to 25%—develop hypoglycemia unawareness, where autonomic warning symptoms such as sweating and tremor become attenuated or absent [4]. This phenomenon greatly elevates the risk for severe events requiring external assistance, often forcing patients and clinicians to accept higher glucose targets than recommended [5]. Thus, the fear and reality of hypoglycemia continue to restrict the full benefits of modern diabetes therapies and remain a central concern in clinical care.

The implications of hypoglycemia extend well beyond transient physical symptoms. Acute episodes have been associated with a heightened risk of cardiac arrhythmias and myocardial ischemia, linked to autonomic surges and altered cardiac repolarization [6]. Hypoglycemia may also induce a prothrombotic state, increasing platelet activation and coagulation, thereby further raising cardiovascular risk—an especially pertinent issue in people already predisposed to vascular disease [7]. At a neurological level, repeated or severe events can result in cognitive dysfunction, seizures, and, rarely, irreversible brain injury [8]. Importantly, the psychological toll is substantial: persistent fear of hypoglycemia can drive suboptimal self-management, such as intentional hyperglycemia, and contribute to reduced quality of life [9]. Fear of hypoglycemia is a multidimensional phenomenon, involving not only anxiety about experiencing the physical symptoms of hypoglycemia but also apprehension regarding the unpredictability of such episodes, potential social embarrassment, and the risk of harm to oneself or others. As highlighted by Bloomgarden [10], this fear can create a significant emotional burden, leading patients to consciously avoid optimal glycemic targets in order to minimize perceived risk, which paradoxically increases the likelihood of long-term diabetes complications. The need for improved detection and prevention strategies is therefore both medical and psychosocial in nature.

An intriguing example of non-technological innovation in this field is the use of diabetes alert dogs (DADs), often Labradors, trained to detect specific scent markers—volatile organic compounds—in the breath or sweat of individuals during hypoglycemic episodes [11]. Controlled studies and real-world experience suggest that DADs can provide early warnings before symptomatic awareness; facilitating more rapid intervention [12]. Furthermore, beyond physiological safety, the presence of a trained service dog offers meaningful psychosocial benefits, including reduced anxiety and increased independence, especially for children and those experiencing nocturnal hypoglycemia [13]. While challenges remain in standardization and evidence quality, DADs exemplify the value of integrating biological detection with patient-centered care.

Technological advances in CGM have transformed the landscape of hypoglycemia detection and prevention. CGM systems provide near-continuous, subcutaneous glucose data, delivering real-time alerts for actual or impending hypoglycemia. Numerous randomized controlled trials have shown that CGM significantly reduces the frequency and severity of hypoglycemia, especially in those with impaired awareness, while also supporting improved glycemic control [14]. CGM also enables trend analysis and more precise therapy adjustments, thus empowering patients and clinicians to optimize diabetes management and mitigate risk [15].

Sensor-augmented insulin pumps (SAPs) with low glucose suspend (LGS) and predictive low glucose suspend (PLGS) functions represent another major step forward. By integrating CGM data, these devices can automatically halt basal insulin infusion when low or dropping glucose is detected or predicted, thereby reducing the risk of severe hypoglycemia, particularly overnight. Large trials, including the ASPIRE and SMILE studies, have confirmed that SAPs with LGS/PLGS significantly decrease hypoglycemia burden without compromising overall glycemic targets, benefiting high-risk groups such as those with hypoglycemia unawareness [16, 17].

The latest generation of CGM and SAP devices employ artificial intelligence (AI) and machine learning to predict hypoglycemic events before they occur. AI algorithms continuously analyze large streams of glucose data, insulin dosing, and contextual factors in real time, identifying patterns and predicting when blood glucose is likely to fall below a safe threshold. In CGM systems, this can trigger timely alerts to the patient or caregiver before hypoglycemia actually develops, allowing for preventive action. In SAPs and closed-loop systems, AI not only predicts impending hypoglycemia but can automatically adjust or suspend insulin delivery to avert the event. These predictive and automated features are especially valuable at night when patients are most vulnerable and may not be aware of symptoms. Preliminary clinical studies indicate that such predictive technologies can substantially reduce nocturnal hypoglycemia and improve user confidence while the accuracy and personalization of these algorithms continue to advance [18, 19]. As AI-driven systems are integrated into closed-loop insulin delivery, their potential for individualized diabetes management is expected to expand further.

Non-invasive glucose monitoring using sweat, saliva, or transdermal technologies holds significant promise for the future, aiming to reduce the burden of needle-based monitoring and increase adherence. In parallel, wearable health devices—such as smartwatches—are being developed to provide multi-parameter physiologic data, enabling more robust and context-aware hypoglycemia prediction [20]. The evolution of closed-loop “artificial pancreas” systems, which automatically adjust insulin delivery based on real-time sensor data, is moving diabetes management closer to seamless automation, reducing both hypo- and hyperglycemic excursions [21]. The integration of biosensors, digital health solutions, and AI-driven analytics is expected to herald a new era of proactive, individualized diabetes management.

In conclusion, recent innovations in hypoglycemia detection—spanning from the keen instincts of trained dogs to advanced CGMs, SAPs, and AI—have redefined diabetes management. These technologies have not only reduced the risk and burden of hypoglycemia, but also alleviated its psychological consequences, enhancing quality of life and patient autonomy. Where once individuals relied on a dog's bark for protection, today's solutions ensure that warnings are timely, precise, and reliable. For many years, the dog was barking in the middle of the night; at last, now we can enjoy better sleep.

T.K. reviewed the literature and wrote the first version of the manuscript. D.S.P. and N.P. reviewed the literature and edited the manuscript. All authors have read and approved the final version of the manuscript.

T.K. is an Editorial Board member of Journal of Diabetes and a co-author of this article. To minimize bias, they were excluded from all editorial decision-making related to the acceptance of this article for publication. T.K. has received honoraria for lectures from AstraZeneca, Sanofi, Boehringer Ingelheim, Pharmaserve Lilly, Menarini, and Novo Nordisk, for advisory boards from Novo Nordisk, Roche, Sanofi, and Boehringer Ingelheim, and has participated in sponsored studies by Eli-Lilly, AstraZeneca, and Novo Nordisk. D.S.P. declares associations to Abbott, Alkaloid, AstraZeneca, Boehringer-Ingelheim, Berlin-Chemie, Eli Lilly, Galenika, Krka, Merck, Novo Nordisk, PharmaSwiss, Sanofi-Aventis, Servier, Viatris, ADOC Pharma, and Worwag Pharma. N.P. has been an advisory board member of TrigoCare International, Abbott, AstraZeneca, Elpen, MSD, Novartis, Novo Nordisk, Sanofi Aventis, and Takeda; has participated in sponsored studies by Eli Lilly, MSD, Novo Nordisk, Novartis, and Sanofi Aventis; received honoraria as a speaker for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Elpen, Galenica, GSK, MSD, Mylan, Novartis, Novo Nordisk, Pfizer, Sanofi Aventis, Takeda, and Vianex; and attended conferences sponsored by TrigoCare International, AstraZeneca, Boehringer Ingelheim, Eli Lilly, GSK, Novartis, Novo Nordisk, Pfizer, and Sanofi Aventis.

狗在叫:通过创新的低血糖检测改变糖尿病患者的生活质量
大量随机对照试验表明,CGM可显著降低低血糖的发生频率和严重程度,特别是在认知受损的患者中,同时也有助于改善血糖控制。CGM还支持趋势分析和更精确的治疗调整,从而使患者和临床医生能够优化糖尿病管理并降低风险。具有低糖暂停(LGS)和预测低糖暂停(PLGS)功能的传感器增强胰岛素泵(sap)代表了另一个重要的进步。通过整合CGM数据,这些设备可以在检测到或预测到低血糖或下降时自动停止基础胰岛素输注,从而降低严重低血糖的风险,特别是在夜间。包括ASPIRE和SMILE研究在内的大型试验已经证实,具有LGS/PLGS的SAPs可显著降低低血糖负担,而不会影响总体血糖目标,使低血糖意识不清的高危人群受益[16,17]。最新一代的CGM和SAP设备采用人工智能(AI)和机器学习来预测低血糖事件的发生。人工智能算法持续实时分析大量葡萄糖数据流、胰岛素剂量和环境因素,识别模式并预测血糖何时可能低于安全阈值。在CGM系统中,这可以在低血糖实际发生之前及时向患者或护理人员发出警报,从而采取预防措施。在sap和闭环系统中,人工智能不仅可以预测即将发生的低血糖,还可以自动调整或暂停胰岛素的输送以避免这一事件。这些预测性和自动化功能在夜间尤其有价值,因为夜间患者最脆弱,可能没有意识到症状。初步的临床研究表明,这种预测技术可以显著降低夜间低血糖,提高用户信心,同时这些算法的准确性和个性化也在不断提高[18,19]。随着人工智能驱动的系统被整合到闭环胰岛素输送中,它们在个性化糖尿病管理方面的潜力有望进一步扩大。使用汗液、唾液或透皮技术的无创血糖监测在未来具有重要的前景,旨在减轻针头监测的负担并增加依从性。与此同时,可穿戴健康设备(如智能手表)正在开发中,以提供多参数生理数据,从而实现更强大的情境感知低血糖预测。闭环“人工胰腺”系统的发展,可以根据实时传感器数据自动调整胰岛素的输送,使糖尿病管理更接近无缝自动化,减少低血糖和高血糖的发生。生物传感器、数字健康解决方案和人工智能驱动分析的整合有望预示着主动、个性化糖尿病管理的新时代。总之,最近在低血糖检测方面的创新——从训练有素的狗的敏锐本能到先进的cgm、sap和人工智能——重新定义了糖尿病管理。这些技术不仅降低了低血糖的风险和负担,而且减轻了低血糖的心理后果,提高了患者的生活质量和自主性。曾经人们依靠狗叫来保护自己,今天的解决方案确保了警告的及时、精确和可靠。多年来,狗在半夜叫;最后,现在我们可以享受更好的睡眠。查阅文献并撰写第一版手稿。D.S.P.和N.P.审阅了文献并编辑了手稿。所有作者都已阅读并批准了最终版本的手稿。是《糖尿病杂志》的编辑委员会成员,也是本文的合著者。为了尽量减少偏倚,他们被排除在与接受这篇文章发表有关的所有编辑决策之外。T.K.曾获得阿斯利康、赛诺菲、勃林格殷格翰、药学礼来、美纳里尼和诺和诺德的讲座荣誉,以及诺和诺德、罗氏、赛诺菲和勃林格殷格翰的顾问委员会荣誉,并参与了由礼来、阿斯利康和诺和诺德赞助的研究。D.S.P.宣布与雅培、生物碱、阿斯利康、勃林格-英格翰、柏林化学、礼来、Galenika、Krka、默克、诺和诺德、PharmaSwiss、赛诺菲-安万特、施维雅、Viatris、ADOC Pharma和Worwag Pharma的关联。N.P. 曾担任TrigoCare International、Abbott、AstraZeneca、Elpen、MSD、Novartis、Novo Nordisk、Sanofi Aventis和Takeda的顾问委员会成员;曾参与礼来、默沙东、诺和诺德、诺华和赛诺菲安万特赞助的研究;作为阿斯利康、勃林格殷格翰、礼来、Elpen、Galenica、GSK、MSD、Mylan、诺华、诺和诺德、辉瑞、赛诺菲安万特、武田和Vianex的演讲嘉宾获得荣誉;并参加了由TrigoCare国际、阿斯利康、勃林格殷格翰、礼来、葛兰素史克、诺华、诺和诺德、辉瑞和赛诺菲安万特赞助的会议。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Diabetes
Journal of Diabetes ENDOCRINOLOGY & METABOLISM-
CiteScore
6.50
自引率
2.20%
发文量
94
审稿时长
>12 weeks
期刊介绍: Journal of Diabetes (JDB) devotes itself to diabetes research, therapeutics, and education. It aims to involve researchers and practitioners in a dialogue between East and West via all aspects of epidemiology, etiology, pathogenesis, management, complications and prevention of diabetes, including the molecular, biochemical, and physiological aspects of diabetes. The Editorial team is international with a unique mix of Asian and Western participation. The Editors welcome submissions in form of original research articles, images, novel case reports and correspondence, and will solicit reviews, point-counterpoint, commentaries, editorials, news highlights, and educational content.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信